Jeremy M Force, DO

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Email address jeremy.force@duke.edu

Education and Training

  • Hematology/Oncology Fellowship, Medicine, Duke University School of Medicine, 2014 - 2017
  • Internal Medicine Residency, Indiana University, School of Medicine, 2011 - 2014
  • D.O., University of New England, 2011

Grants

Publications

Plichta, Jennifer K., Samantha M. Thomas, Amanda R. Sergesketter, Rachel A. Greenup, Laura H. Rosenberger, Oluwadamilola M. Fayanju, Gretchen Kimmick, Jeremy Force, Terry Hyslop, and E Shelley Hwang. “A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates.” Ann Surg 275, no. 4 (April 1, 2022): 784–92. https://doi.org/10.1097/SLA.0000000000004231.

PMID
32657941
Full Text

DiMarco, Ashley V., Xiaodi Qin, Brock J. McKinney, Nina Marie G. Garcia, Sarah C. Van Alsten, Elizabeth A. Mendes, Jeremy Force, et al. “APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.” Cancer Immunol Res 10, no. 1 (January 2022): 70–86. https://doi.org/10.1158/2326-6066.CIR-21-0146.

PMID
34795033
Full Text

Burnette, S., E. Poehlein, H. -. J. Lee, J. Force, K. Westbrook, and H. Moore. “253P Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) + fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC).” In Annals of Oncology, 32:S470–S470. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.536.

Full Text

Drusbosky, Leylah, Mehmet Asim Bilen, Georges Azzi, Pedro C. Barata, Patrick M. Boland, Alan Haruo Bryce, Young Kwang Chae, et al. “Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.” In Journal of Clinical Oncology, 39:3040–3040. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.3040.

Full Text

Sammons, Sarah, Andrew Elliott, Jeremy Meyer Force, Nicholas C. DeVito, Paul Kelly Marcom, Sandra M. Swain, Antoinette R. Tan, et al. “Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.” In Journal of Clinical Oncology, 39:1091–1091. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.1091.

Full Text

Taylor, Mary Love, Hiba I. Dada, Hannah Florian, Paul Kelly Marcom, Carey K. Anders, Leylah Drusbosky, and Jeremy Meyer Force. “Identification of pathogenic CDK12 alterations in cell-free DNA (cfDNA) from patients with breast cancer.” In Journal of Clinical Oncology, 39:1028–1028. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.1028.

Full Text

Tamirisa, Nina P., Yi Ren, Brittany M. Campbell, Samantha M. Thomas, Oluwadamilola M. Fayanju, Jennifer K. Plichta, Laura H. Rosenberger, et al. “Treatment Patterns and Outcomes of Women with Breast Cancer and Supraclavicular Nodal Metastases.” Ann Surg Oncol 28, no. 4 (April 2021): 2146–54. https://doi.org/10.1245/s10434-020-09024-1.

PMID
32946012
Full Text

Isaacs, James, Carey Anders, Heather McArthur, and Jeremy Force. “Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.” Curr Treat Options Oncol 22, no. 5 (March 20, 2021): 38. https://doi.org/10.1007/s11864-021-00833-4.

PMID
33743085
Full Text

Taylor, Mary Love, Benjamin Mayro, Leylah Drusbosky, Robin Batchelder, P Kelly Marcom, Carey Anders, and Jeremy Force. “Identification of pathogenic FGFR1, FGFR2, and FGFR3 alterations in cell-free DNA (cfDNA) from patients with metastatic breast cancer.” In Cancer Research, Vol. 81, 2021.

Scholars@Duke

Pages